advertisement
Drugs 17
Showing records 1 to 17 | Display all abstracts in Drugs126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Silverstein SM
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Mann E
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Oddone F
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Kammer JA
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Kolko M
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Sawhney G
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Brinkmann CK
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
An J
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Christie WC
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Werts EC
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Bicket AK
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Vera V; Rivas M
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Gous PNJ; Luebke J
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Lai H
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Maram J
Drugs 2025; 85: 557-570
126957 Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice
Sonparote S; Craven ER
Drugs 2025; 85: 397-414
126960 Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)
Nguyen A; Craven ER; Pu Y; Jiao J; Bejanian M; Robinson MR;
Drugs 2025; 85: 557-570
